{
    "nct_id": "NCT04417517",
    "official_title": "A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)",
    "inclusion_criteria": "* Phase 1: Diagnosis of higher risk MDS that is either previously untreated or relapsed/refractory.\n* Phase 2: Diagnosis of higher risk MDS that is previously untreated.\n* Adequate renal and liver function.\n* Age ≥18 years.\n* Adequate performance status.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous allogeneic hematopoietic stem cell transplant (allo-HSCT) for MDS or AML.\n* Prior treatment with any anti-CD47 or anti-SIRPα (signal regulatory protein alpha) agent.\n* Known active viral infections, including hepatitis B and C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS) related illness, or SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2).",
    "miscellaneous_criteria": ""
}